Janux Therapeutics reports Q3 EPS (51c), consensus (33c)

Reports Q3 revenue $439,000, consensus $1.64M. The company said, “Our efforts remain focused on enrolling participants in the PSMA-TRACTr (JANX007) and EGFR-TRACTr (JANX008) clinical trials, and we are encouraged by our continued progress. We look forward to providing an update on our JANX007 program by year end.” As of September 30, Janux reported cash and cash equivalents and short-term investments of $658.0M compared to $344.0M at December 31, 2023.